PALO ALTO, Calif. / Dec 20, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 8, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
| Last Trade: | US$65.26 |
| Daily Change: | -0.06 -0.09 |
| Daily Volume: | 1,167,521 |
| Market Cap: | US$8.140B |
September 24, 2025 September 15, 2025 September 11, 2025 September 08, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
